Correct Answer: A. Topiramate
Topiramate is the antiseizure drug most strongly associated with calcium-based renal stones among the options listed. 1, 2
Why Topiramate is Correct
Topiramate possesses carbonic anhydrase inhibition properties, which is the key mechanism driving stone formation. 1 This pharmacologic action leads to:
- Renal tubular acidosis and subsequent urolithiasis through altered urinary chemistry 1
- Decreased urinary citrate excretion (hypocitraturia), which removes a critical inhibitor of calcium phosphate crystallization 3
- Increased urinary pH, promoting calcium phosphate precipitation 3
- Calcium phosphate stones as the predominant stone type, though calcium oxalate risk may also increase 3, 2
The association between topiramate and kidney stones is well-documented in the literature, with this adverse effect being "particularly associated" with the drug. 2
Why the Other Options are Incorrect
B. Lacosamide
- No documented association with renal stone formation in the provided evidence
- Does not possess carbonic anhydrase inhibition properties
- Not mentioned in any of the studies addressing antiepileptic drug-related nephrolithiasis 1, 2
C. Sodium Valproate
- Associated with Fanconi syndrome in severely disabled children with epilepsy, not renal stones 1
- Causes markers of renal glomerular and tubular injury (elevated urinary NAG/creatinine ratios) with chronic use 1
- Induces oxidative stress, mitochondrial deficits, and inflammation in renal tissue, but this does not translate to stone formation 1
- The renal complications are fundamentally different from stone disease
D. Levetiracetam
- No documented association with renal calculi in the evidence provided
- Not mentioned among antiepileptic drugs causing kidney stones 1, 2
- Generally considered to have a favorable renal safety profile
Clinical Context: Other Carbonic Anhydrase Inhibitors
It's worth noting that other antiseizure drugs with carbonic anhydrase inhibition share this stone-forming propensity:
- Acetazolamide: Well-documented cause of calcium phosphate stones, with cases of recurrent calculi and irreversible renal damage reported 4, 3
- Zonisamide: Associated with renal calculi, though the absolute risk appears low (1.2–1.4% in clinical trials) 1, 5, 2
The mechanism is consistent across this drug class: carbonic anhydrase inhibition → urinary alkalinization + hypocitraturia → calcium phosphate supersaturation and crystallization. 3, 1